Overview

Data as of October 20, 2019 11:09 am EDT

Press Releases

Summary Toggle Madrigal Pharmaceuticals Reports 2019 Second Quarter Financial Results and Highlights

August 07, 2019

-- Phase 3 MAESTRO-NASH Program Continues to Progress -- -- Jim Daly Added to Board of Directors and Becky Taub Promoted to President of R&D -- -- Madrigal Presentations Selected for the Liver Meeting ® AASLD 2019 in Boston , November 2019 -- CONSHOHOCKEN, Pa. , Aug.
Summary Toggle Madrigal Pharmaceuticals Promotes Rebecca Taub, M.D., Chief Medical Officer and Executive Vice President of Research & Development, to Newly Created Position of President of Research & Development

July 11, 2019

-- Dr. Taub to present at the 5th Paris NASH Meeting to be held on July 11-12, 2019 -- CONSHOHOCKEN, Pa. , July 11, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today the promotion of Rebecca Taub , M.D., to the newly created positon of President of Research &
Summary Toggle Madrigal Pharmaceuticals Announces Appointment of Jim Daly to Board of Directors

July 02, 2019

CONSHOHOCKEN, Pa. , July 02, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that Jim Daly has been appointed to the Company’s Board of Directors, as a Class I director, effective as of June 27 , 2019. “We are extremely pleased to have an executive with Jim’s

Filing date	Form	Description	Filing Group	View
July 05, 2017	D		Other	0001288452-17-000002.rtf 0001288452-17-000002.pdf
April 17, 2013	PRE 14A	A preliminary proxy statement providing notification matters to be brought to a vote	Proxy Filings	0001047469-13-004491.rtf 0001047469-13-004491.xls 0001047469-13-004491.pdf
May 19, 2016	PREM14A	A preliminary proxy statement relating to a merger or acquisition	Mergers & Acquisitions	0001047469-16-013282.rtf 0001047469-16-013282.xls 0001047469-16-013282.pdf